Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission file number: 001-41518

Qomolangma Acquisition Corp.

(Exact name of registrant as specified in its charter)

Delaware		86-3733656
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1178 Broadway, 3^rd Floor

New York, NY 10010

(Address of principal executive offices)

(646) 791-7587

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units	QOMOU	The Nasdaq Stock Market LLC
Common Stock	QOMO	The Nasdaq Stock Market LLC
Warrants	QOMOW	The Nasdaq Stock Market LLC
Rights	QOMOR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of November 13, 2023, there were 3,575,635 shares of the registrant’s common stock, $0.0001 par value, issued and outstanding.

QOMOLANGMA ACQUISITION CORP.

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023
TABLE OF CONTENTS

			Page
Part I – Financial Information			1
	Item 1.	Financial Statements.	1
		Condensed Balance Sheets as of September 30, 2023 (Unaudited) and December 31,2022 (Audited)	1
		Unaudited Condensed Statements of Operations for the Three and Nine Months ended September 30, 2023 and 2022	2
		Unaudited Condensed Statements of Changes in Stockholders’ Equity (Deficit) for the Three and Nine Months ended September 30, 2023 and 2022	3
		Unaudited Condensed Statements of Cash Flows for the Nine Months ended September 30, 2023 and 2022	4
		Notes to Unaudited Condensed Financial Statements	5
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
	Item 4.	Controls and Procedures	23
Part II – Other Information			24
	Item 1.	Legal Proceedings	24
	Item 1A.	Risk Factors	24
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
	Item 3.	Defaults Upon Senior Securities	24
	Item 4.	Mine Safety Disclosures	24
	Item 5.	Other Information	24
	Item 6.	Exhibits	25
Signatures			26

Part I – Financial Information

Item 1. Financial Statements.

QOMOLANGMA ACQUISITION CORP.
CONDENSED BALANCE SHEETS

	September 30, 2023			December 31, 2022
	(Unaudited)			(Audited)
Assets
Current Assets
Cash	$	46,617		$	196,510
Prepaid expenses		122,900			235,476
Total Current Assets		169,517			431,986

Investments held in Trust Account		33,720,333			53,958,681
Total Assets	$	33,889,850		$	54,390,667

Liabilities, Temporary Equity, and Stockholders’ Equity
Current Liabilities
Accrued expenses	$	719,385		$	96,212
Accrued expenses – related party		118,387			28,387
Franchise tax payable		30,700			45,428
Income tax payable		394,514			46,115
Excise tax liability		352,241			—
Redeemed common stock payable to public stockholders		13,082,703			—
Promissory note - related party		792,252			155,025
Total Current Liabilities		15,490,182			371,167

Deferred tax liability		30,178			36,164
Deferred underwriting fee payable		2,109,200			2,109,200
Total Liabilities		17,629,560			2,516,531

Commitments and Contingencies

Common stock subject to possible redemption, $0.0001 par value; 16,000,000 shares authorized; 1,913,012 shares and 5,273,000 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively, at redemption value of $10.57 and $10.22 at September 30, 2023 and December 31, 2022, respectively		20,181,740			46,828,833

Stockholders’ Equity (Deficit)
Common stock, $0.0001 par value; 16,000,000 shares authorized; 1,662,623 shares issued and outstanding (excluding 1,913,012 shares 5,273,000 shares subject to possible redemption at September 30, 2023 and December 31, 2022, respectively)		166			166
Additional paid-in capital		—			4,914,221
(Accumulated deficit) Retained earnings		(3,921,616	)		130,916
Total Stockholders’ Equity (Deficit)		(3,921,450	)		5,045,303
Total Liabilities, Temporary Equity, and Stockholders’ Equity	$	33,889,850		$	54,390,667

The accompanying notes are an integral part of these unaudited condensed financial statements.

QOMOLANGMA ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022

General and administrative expenses	$	344,212		$	122		$	1,325,643		$	7,271
Franchise tax expenses		6,900			(5,136	)		30,700			—
Income (loss) from operations		(351,112	)		5,014			(1,356,343	)		(7,271	)

Interest earned on investments held in Trust Account		439,145			—			1,661,237			—
Income (loss) before income taxes		88,033			5,014			304,894			(7,271	)

Income taxes provision		(90,772	)		—			(342,413	)		—
Net income (loss)	$	(2,739	)	$	5,014		$	(37,519	)	$	(7,271	)

Basic and diluted weighted average shares outstanding, redeemable common stock		2,904,816			—			4,448,538			—

Basic and diluted net income per share, redeemable common stock	$	0.05		$	—		$	0.52		$	—

Basic and diluted weighted average shares outstanding, non-redeemable common stock		1,662,623			1,250,000	⁽¹⁾		1,662,623			1,250,000	⁽¹⁾

Basic and diluted net income (loss) per share, non-redeemable common stock	$	(0.09	)	$	0.00		$	(1.41	)	$	(0.01	)

(1)

Excludes up to 187,500 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part (see Note 5). On October 4, 2022, the underwriters partially exercised the over-allotment option resulting in forfeiture of 119,250 shares of common stock.

The accompanying notes are an integral part of these unaudited condensed financial statements.

QOMOLANGMA ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

For the Nine Months Ended September 30, 2023

	Common stock				Additional Paid-in			Retained Earnings (Accumulated			Total Stockholders’
	Shares		Amount		Capital			Deficit)			Equity (Deficit)
Balance as of January 1, 2023		1,662,623	$	166	$	4,914,221		$	130,916		$	5,045,303
Accretion of common stock to redemption value		—		—		(3,802,141	)		—			(3,802,141	)
Net loss		—		—		—			(224,171	)		(224,171	)
Balance as of March 31, 2023		1,662,623	$	166	$	1,112,080		$	(93,255	)	$	1,018,991
Accretion of common stock to redemption value		—		—		(1,112,080	)		(3,274,072	)		(4,386,152	)
Excise tax liability		—		—		—			(221,414	)		(221,414	)
Net income		—		—		—			189,391			189,391
Balance as of June 30, 2023		1,662,623	$	166	$	—		$	(3,399,350	)	$	(3,399,184	)
Accretion of common stock to redemption value		—		—		—			(388,700	)		(388,700	)
Excise tax liability		—		—		—			(130,827	)		(130,827	)
Net loss		—		—		—			(2,739	)		(2,739	)
Balance as of September 30, 2023		1,662,623	$	166	$	—		$	(3,921,616	)	$	(3,921,450	)

For the Nine Months Ended September 30, 2022

	Common Stock				Additional Paid-In		Accumulated			Total Stockholders’
	Shares ⁽¹⁾		Amount		Capital		Deficit			Equity
Balance as of January 1, 2022		1,437,500	$	144	$	24,856	$	(3,935	)	$	21,065
Net loss		—		—		—		(7,318	)		(7,318	)
Balance as of March 31, 2022		1,437,500	$	144	$	24,856	$	(11,253	)	$	13,747
Net loss		—		—		—		(4,967	)		(4,967	)
Balance as of June 30, 2022		1,437,500	$	144	$	24,856	$	(16,220	)	$	8,780
Net loss		—		—		—		5,014			5,014
Balance as of September 30, 2022		1,437,500	$	144	$	24,856	$	(11,206	)	$	13,794

(1)

Includes up to 187,500 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part (see Note 5). On October 4, 2022, the underwriters partially exercised the over-allotment option resulting in forfeiture of 119,250 shares of common stock.

The accompanying notes are an integral part of these unaudited condensed financial statements.

QOMOLANGMA ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS

	Nine Months Ended September 30,
	2023			2022
Cash flows from operating activities:
Net loss	$	(37,519	)	$	(7,271	)
Adjustments to reconcile net cash used in operating activities:
Interest earned on investments held in Trust Account		(1,661,237	)		—
Deferred income tax		(5,986	)		—
Changes in current assets and current liabilities:
Prepaid expenses		112,576			—
Accrued expenses		623,173			—
Accrued expenses – related party		90,000			—
Franchise tax payable		(14,728	)		—
Income tax payable		348,399			—
Net cash used in operating activities		(545,322	)		(7,271	)

Cash Flows from Investing Activities:
Cash withdrawal from Trust Account to pay franchise tax		45,429			—
Cash withdrawal from Trust Account to pay public stockholder redemptions		22,141,383			—
Net cash provided by investing activities		22,186,812			—

Cash Flows from Financing Activities:
Repayment to related party advances		—			(1,500	)
Proceeds from issuance of promissory note to related party		350,000			—
Payment of public stockholder redemptions		(22,141,383	)		—
Payment of deferred offering costs		—			(90,530	)
Net cash used in financing activities		(21,791,383	)		(92,030	)

Net change in cash		(149,893	)		(99,301	)
Cash, beginning of the period		196,510			154,565
Cash, end of the period	$	46,617		$	55,264

Supplemental Disclosure of Non-cash Investing and Financing Activities
Deferred offering costs in accrued offering costs	$	—		$	65,000
Excise tax liability accrued for common stock redemption	$	352,241		$	—
Accretion of Common stock to redemption value	$	8,576,993		$	—
Redeemed common stock payable to public stockholders	$	13,082,703		$	—
Extension fee deposited into Trust Account by the Sponsor through issuance of Promissory Note	$	287,227		$	—

The accompanying notes are an integral part of these unaudited condensed financial statements.

QOMOLANGMA ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Note 1 — Description of Organization and Business Operations

Qomolangma Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated as a Delaware corporation on May 6, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (“Business Combination”). The Company intends to pursue target businesses that are strategically significant in the Asian markets and focus on businesses with a total enterprise value of between $300,000,000 and $500,000,000.

As of September 30, 2023, the Company had not commenced any operations. All activities through September 30, 2023 are related to the Company’s formation and the proposed initial public offering (“IPO” as defined below) and, subsequent to the IPO, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.

The Company’s sponsor is Qomolangma Investments LLC (the “Sponsor”), a Delaware limited liability company.

The registration statement for the Company’s IPO became effective on September 29, 2022. On October 4, 2022, the Company consummated the IPO of 5,000,000 units at an offering price of $10.00 per unit (the “Public Units’), generating gross proceeds of $50,000,000. Simultaneously with the closing of the IPO, the Company sold to the Sponsor, in a private placement, 260,500 units, at $10.00 per unit (the “Private Units”), generating total gross proceeds of $2,605,000.

Transaction costs from the IPO amounted to $4,222,030, consisting of $875,000 of underwriting fees, $2,000,000 of deferred underwriting fees (payable only upon completion of a Business Combination) and $1,347,030 of other offering costs.

The Company granted the underwriter a 45-day option to purchase up to 750,000 additional Public Units to cover over-allotments, if any. On October 4, 2022, the underwriter partially exercised the over-allotment option and purchased 273,000 Public Units at a price of $10.00 per Public Unit on October 7, 2022, generating gross proceeds of $2,730,000. Simultaneously with the closing of the over-allotment option, the Company consummated the private placement of an additional 8,873 Private Units generating gross proceeds of $88,725.

A total of $53,520,950 ($10.15 per Unit) of the net proceeds from the sale of Units in the IPO (including the Over-Allotment Option Units) and the private placements on October 4, 2022 and October 7, 2022, was placed in a trust account (the “Trust Account”) maintained by American Stock Transfer & Trust Company as a trustee and are invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the “Investment Company Act”), and that invest only in direct U.S. government treasury obligations. These funds will not be released until the earlier of the completion of the initial Business Combination and the liquidation due to the Company’s failure to complete a Business Combination within the applicable period of time. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders. In addition, interest income earned on investments held in the Trust Account may be released to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred by the Company may be paid prior to a Business Combination only from the net proceeds of the IPO and private placement not held in the Trust Account.

Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

The Company will provide its holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.15 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income tax obligations).

The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares of common stock voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor and any of the Company’s officers or directors that may hold Founder Shares (as defined in Note 5) (the “Initial Stockholders”) and the underwriters have agreed (a) to vote their Founder Shares, Private Shares (as defined in Note 4), and any Public Shares purchased during or after the IPO in favor of approving a Business Combination and (b) not to convert any shares (including the Founder Shares) in connection with a stockholder vote to approve, or sell the shares to the Company in any tender offer in connection with, a proposed Business Combination.

The Initial Stockholders have agreed (a) to waive their redemption rights with respect to the Founder Shares, Private Shares, and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose, or vote in favor of, an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

Initially, the Company had until July 4, 2023 (or up to July 4, 2024 if the time to complete a business combination is extended as described herein) to consummate a Business Combination. In addition, if the Company anticipated that it would not be able to consummate a Business Combination within 9 months, the Company was able to extend the period of time to consummate a Business Combination up to twelve times, each by an additional one month (for a total of 21 months to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination, the Company’s insiders or their affiliates or designees, upon five days’ advance notice prior to the applicable deadline, was required to deposit into the Trust Account $174,009 ($0.033 per Public Share per month), on or prior to the date of the applicable deadline, for each extension.

On June 29, 2023, the Company held a special meeting of stockholders (the “June Special Meeting”). At the June Special Meeting, the stockholders amended the Company’s Amended and Restated Certificate of Incorporation to allow the Company to consummate a business combination until August 4, 2023 (or up to August 4, 2024 if the time to complete a business combination is extended as described herein) to consummate a Business Combination. In addition, if the Company anticipates that it may not be able to consummate a Business Combination by August 4, 2023, the Company may extend the period of time to consummate a Business Combination up to twelve times, each by an additional one month (for a total of 22 months to complete a Business Combination) (the “Combination Period”). In order to extend the time available for the Company to consummate a Business Combination, the Company’s insiders or their affiliates or designees, upon five days’ advance notice prior to the applicable deadline, must deposit into the Trust Account the lesser of $0.033 per outstanding share and $80,000 per month, on or prior to the date of the applicable deadline, for each extension.

In connection with the June Special Meeting, an aggregate of 2,126,934 shares with redemption value of approximately $22,141,383 (or $10.41 per share) of the Company’s common stock were tendered for redemption.

On June 29, 2023, the Sponsor made a deposit of $240,000 to the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from July 4, 2023 to October 4, 2023.

On September 12, 2023, the Company held a special meeting of stockholders (the “September Special Meeting”). At the Special Meeting, the stockholders amended the Company’s Amended and Restated Certificate of Incorporation to allow the Company to undertake an initial business combination with an entity or business, with a physical presence, operation, or other significant ties to China (a “China-based Target”) or which may subject the post-business combination business to the laws, regulations and policies of China (including Hong Kong and Macao), or entity or business that conducts operations in China through variable interest entities, or VIEs, pursuant to a series of contractual arrangements with the VIE and its shareholders on one side, and a China-based subsidiary of the China-based Target, on the other side.

In connection with the September Special Meeting, an aggregate of 1,233,054 shares with redemption value of approximately $13,082,703 (or $10.61 per share) of the Company’s common stock were tendered for redemption.

On October 31, 2023, the Sponsor made a deposit of $63,129 into the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from November 3, 2023 to December 3, 2023.

If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (which interest shall be net of taxes payable, and less certain amount of interest to pay dissolution expenses) divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder Shares and Private Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor or underwriters acquires Public Shares in or after the IPO, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than $10.15.

In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.15 per Public Share, except as to any claims by a third party who executed a valid and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims.

Liquidity, Capital Resources and Going Concern

As of September 30, 2023, the Company had $46,617 of cash held outside its Trust Account and a working capital deficit of $1,812,748 (excluding redeemed common stock payable to public stockholders, income tax and franchise tax payable as redemptions and taxes are paid out of the Trust Account). On March 22, 2023, June 26, 2023, September 12, 2023, September 26, 2023 and October 26, 2023, the Sponsor loaned the Company $200,000, $240,000, $150,000, $47,227, and $145,000 respectively, to be used, in part, for transaction costs related to the Business Combination and to fund the amount required to extend the Business Combination Period. All promissory notes bear no interest and are repayable in full upon the consummation of the Company’s Business Combination.

As a result of the Sponsor’s deposit of $63,129 to the Trust Account on October 31, 2023, the Company has until December 3, 2023 (unless the Company extends the time to complete a Business Combination) to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution.

The Company expects to continue to incur significant professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of a Business Combination. The Company may need to obtain additional financing either to complete its Business Combination or because it becomes obligated to redeem a significant number of public shares upon consummation of its Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is unable to complete its Business Combination because it does not have sufficient funds available, it will be forced to cease operations and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet its obligations.

In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company is unable to complete a Business Combination within the Combination Period, the Company’s board of directors would proceed to commence voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. As a result, management has determined that such an additional condition also raises substantial doubt about the Company’s ability to continue as a going concern. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.

Risks and Uncertainties

Management has evaluated the impact of current conflicts around the globe, including Russia’s invasion of Ukraine and the Israel-Hamas war, and related sanctions on the world economy, which is not determinable as of the date of these financial statements, and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of these risks and uncertainties.

Inflation Reduction Act of 2022

On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The IR Act applies only to repurchases that occur after December 31, 2022.

Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, it could cause a reduction in the value of the Company’s stock as well as a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete a Business Combination.

As a result of the redemptions by the public stockholders in June and September 2023, the Company recorded total excise tax liability of $352,241 as of September 30, 2023. The Company will continue to monitor for updates to the Company’s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company’s tax provision in future periods.

Note 2 — Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected through December 31, 2023 or for any future periods. These financial statements should be read in conjunction with the Company’s 2022 Annual Report on Form 10-K as filed with the SEC on April 7, 2023.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

In preparing these unaudited financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $46,617 and $196,510 in cash and none in cash equivalents as of September 30, 2023 and December 31, 2022, respectively.

Investments Held in Trust Account

The Company’s portfolio of investments held in the Trust Account is comprised of investments in money market funds that invest in U.S. government securities. These securities are presented on the balance sheets at fair value at the end of each reporting period. Earnings on investments held in the Trust Account are included in interest earned on investments held in the Trust Account in the accompanying unaudited statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that is included in the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

The Company began to earn taxable income from the interest income earned from the Trust Account after the IPO that was consummated on October 4, 2022. The Company’s effective tax rate was 103.11% and 0.00% for the three months ended September 30, 2023 and 2022, respectively. The effective tax rate was 112.31% and 0.00% for the nine months ended September 30, 2023 and 2022, respectively. The effective tax rate differs from the statutory tax rate of 21% for both the three and nine months ended September 30, 2023 and 2022, due to the valuation allowance on the deferred tax assets.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.

While ASC 740 identifies usage of an effective annual tax rate for purposes of an interim provision, it does allow for estimating individual elements in the current period if they are significant, unusual or infrequent. Computing the effective tax rate for the Company is complicated due to the potential impact of the timing of any Business Combination expenses and the actual interest income that will be recognized during the year. The Company has taken a position as to the calculation of income tax expense in a current period based on ASC 740-270-25-3 which states, “If an entity is unable to estimate a part of its ordinary income (or loss) or the related tax (benefit) but is otherwise able to make a reasonable estimate, the tax (or benefit) applicable to the item that cannot be estimated shall be reported in the interim period in which the item is reported.” The Company believes its calculation to be a reliable estimate and allows it to properly take into account the usual elements that can impact its annualized book income and its impact on the effective tax rate. As such, the Company is computing its taxable income (loss) and associated income tax provision based on actual results for the three and nine month periods ended September 30, 2023 and 2022.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

The Company has identified the United States as its only “major” tax jurisdiction.

The Company may be subject to potential examination by federal and state taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

Net Income (Loss) Per Share

The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. The statements of operations include a presentation of income (loss) per redeemable share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public shareholders. As of September 30, 2023 and 2022, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. The Company has not considered the effect of the warrants and rights in the calculation of diluted income (loss) per share, since the exercise of the warrants and rights are contingent upon the occurrence of future events. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented.

The net income (loss) per share presented in the unaudited condensed statements of operations is based on the following:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2023			2022		2023			2022
Net income (loss)	$	(2,739	)	$	5,014	$	(37,519	)	$	(7,271	)
Accretion of common stock to redemption value		(388,700	)		—		(8,576,993	)		—
Net income (loss) including accretion of common stock to redemption value	$	(391,439	)	$	5,014	$	(8,614,512	)	$	(7,271	)

	Three Months Ended September 30, 2023						Nine Months Ended September 30, 2022
	Redeemable share			Non- redeemable shares			Redeemable shares		Non- redeemable shares
Basic and diluted net income/(loss) per share:
Numerator:
Allocation of net income (loss) including accretion of common stock	$	(248,949	)	$	(142,490	)	$	—	$	5,014
Accretion of common stock to redemption value		388,700			—			—		—
Allocation of net income (loss)	$	139,751		$	(142,490	)	$	—	$	5,014

Denominator:
Basic and diluted weighted average shares outstanding		2,904,816			1,662,623			—		1,250,000
Basic and diluted net income (loss) per share	$	0.05		$	(0.09	)	$	—	$	0.00

	Nine Months Ended September 30, 2023						Nine Months Ended September 30, 2022
	Redeemable share			Non- redeemable shares			Redeemable shares		Non- redeemable shares
Basic and diluted net income/(loss) per share:
Numerator:
Allocation of net income (loss) including accretion of common stock	$	(6,270,820	)	$	(2,343,692	)	$	—	$	(7,271	)
Accretion of common stock to redemption value		8,576,993			—			—		—
Allocation of net income (loss)	$	2,306,173		$	(2,343,692	)	$	—	$	(7,271	)

Denominator:
Basic and diluted weighted average shares outstanding		4,448,538			1,662,623			—		1,250,000
Basic and diluted net income (loss) per share	$	0.52		$	(1.41	)	$	—	$	(0.01	)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of September 30, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Fair Value of Financial Instruments

FASB ASC Topic 820 “Fair Value Measurements and Disclosures” defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. FASB ASC Topic 820 establishes a fair value hierarchy for inputs, which represent the assumptions used by the buyer and seller in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that the buyer and seller would use in pricing the asset or liability developed based on the best information available in the circumstances.

The fair value hierarchy is categorized into three levels based on the inputs as follows:

Level 1

Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment.

Level 2

Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means.

Level 3

Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The fair value of the Company’s certain assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the consolidated balance sheet. The fair values of cash, other current assets, accrued expenses, and due to sponsor are estimated to approximate the carrying values as of September 30, 2023 and December 31, 2022 due to the short maturities of such instruments. See Note 8 for the disclosure of the Company’s assets and liabilities that were measured at fair value on a recurring basis.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Consequently, the Company accounts for warrants as equity-classified instruments.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.

Common Stock Subject to Possible Redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheets.

The Company has made a policy election in accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in additional paid-in capital or accumulated deficit if additional paid-in capital equals to zero, over an expected 9-month period leading up to a Business Combination. As of September 30, 2023, the Company recorded $ 11,986,633 total accretion of redeemable common stock to redemption value.

At December 31, 2022 and September 30, 2023, the amounts of common stock subject to possible redemption reflected in the balance sheets are reconciled in the following table:

Gross proceeds	$	52,730,000
Less:
Proceeds allocated to public warrants		(3,532,910	)
Proceeds allocated to public rights		(1,845,550	)
Allocation of offering costs related to redeemable shares		(3,932,347	)
Plus:
Accretion of carrying value to redemption value		3,409,640
Common stock subject to possible redemption - December 31, 2022		46,828,833
Plus:
Accretion of carrying value to redemption value – nine months ended September 30, 2023		8,576,993
Redeemed public stockholders ⁽¹⁾		(35,224,086	)
Common stock subject to possible redemption - September 30, 2023	$	20,181,740

(1)	Includes $13,082,703 payment to redeemed public stockholders which was made on October 5, 2023.

Reclassification of Prior Year Presentation

Certain reclassifications have been made between accrued expenses and amount due to a related party, to conform to the current year presentation. The reclassifications did not impact previously reported total current liabilities, total liabilities, the net cash used in operating activities or net cash provided by financing activities.

Recent Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 for the Company and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Note 3 — Initial Public Offering

Pursuant to its IPO on October 4, 2022, the Company sold 5,000,000 Units at a price of $10.00 per Unit, generating gross proceeds of $50,000,000. The Company granted the underwriters a 45-day option to purchase up to 750,000 additional Public Units to cover over-allotments, if any. On October 7, 2022, the underwriter partially exercised the over-allotment option and purchased 273,000 Public Units at a price of $10.00 per Public Unit, generating gross proceeds of $2,730,000. Each Public Unit consists of one share of common stock (“Public Share”), one right (“Public Right”) and one redeemable warrant (“Public Warrant”). Each Public Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination. Each Public Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment. The Public Warrants will become exercisable on the later of 30 days following the completion of the Company’s initial Business Combination or 12 months from the closing of the IPO, and will expire five years after the completion of the Company’s initial Business Combination or earlier upon redemption or liquidation.

All of the 5,273,000 Public Shares sold as part of the Public Units in the IPO (including over-allotment units) contain a redemption feature which allows for the redemption of such Public Shares if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s amended and restated certificate of incorporation, or in connection with the Company’s liquidation. In accordance with the SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity.

The Company’s redeemable common stock is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has made a policy election in accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in accumulated deficit over an expected 9-month period leading up to a Business Combination.

Note 4 — Private Placement

Simultaneously with the closing of the IPO, the Sponsor purchased 260,500 Private Units at a price of $10.00 per Private Unit for an aggregate purchase price of $2,605,000 in a private placement. Simultaneously with the closing of the over-allotment option, the Company consummated the sale of an additional 8,873 Private Units with the Sponsor at a price of $10.00 per Private Unit, generating total proceeds of $88,725. Each Private Unit consists of one share of common stock (“Private Share”), one right (“Private Right”) and one redeemable warrant (“Private Warrant”). Each Private Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination. Each Private Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment. The Private Warrants will be identical to the Public Warrants except that the Private Warrants and the shares of common stock issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until after the completion of a Business Combination. The net proceeds from the Private Units were added to the proceeds from the IPO to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Units and all underlying securities will expire worthless.

Note 5 — Related Party Transactions

Founder Shares

On September 25, 2021, the Company issued 1,437,500 shares of common stock to the Initial Stockholders (the “Founder Shares”) for an aggregated consideration of $25,000, or approximately $0.017 per share.

The Initial Shareholders have agreed to forfeit up to up to 187,500 Founder Shares to the extent that the underwriters’ over-allotment is not exercised in full, so that the Initial Stockholders will collectively own 20% of the Company’s issued and outstanding shares after the IPO (assuming the Initial Stockholders do not purchase any Public Shares in the IPO and excluding the Private Units). As a result of the underwriter’s partial exercise of the over-allotment option on October 4, 2022, 119,250 shares of the Founder Shares were forfeited for no consideration on October 7, 2022 resulting in 1,318,250 Founder Shares outstanding after the forfeiture.

The Initial Stockholders have agreed, subject to certain limited exceptions, not to transfer, assign or sell any of their Founder Shares until, with respect to 50% of the Founder Shares, the earlier of six months after the consummation of a Business Combination and the date on which the closing price of the common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing after a Business Combination and, with respect to the remaining 50% of the Founder Shares, until the six months after the consummation of a Business Combination, or earlier, in either case, if, subsequent to a Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property.

Promissory Note — Related Party

On September 5, 2021, the Sponsor agreed to loan the Company up to an aggregate amount of $200,000 to be used, in part, for transaction costs incurred in connection with the IPO (the “Promissory Note”). The Promissory Note is unsecured, interest-free and due on the closing of the IPO. The Company repaid the outstanding balance of $200,000 to the Sponsor on October 7, 2022.

The Company received $155,025 from the Sponsor at the closing of IPO to finance transaction costs in connection with searching for a target business. On October 7, 2022, the Sponsor converted the outstanding balance of $155,025 to the Promissory Note. On March 22, 2023, June 26, 2023, September 12, 2023 and September 26, 2023, the Sponsor loaned the Company $200,000, $240,000, $150,000, and $47,227 (collectively “Promissory Notes”), respectively, to be used, in part, for extension deposits. Each Promissory Note is unsecured, interest-free and due on the date the Company consummates a business combination.

As of September 30, 2023 and December 31, 2022, $792,252 and $155,025 were outstanding under the Promissory Notes, respectively.

Related Party Loans

In addition, in order to finance transaction costs in connection with searching for a target business or consummating an intended initial business combination, the initial stockholders, officers, directors or their affiliates may, but are not obligated to, loan the Company funds as may be required. In the event that the initial business combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from the Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into Private Units at a price of $10.00 per unit at the option of the lender. The terms of such related party loans, if any, have not been determined and no written agreements exist with respect to such loans.

As of September 30, 2023 and December 31, 2022, the Company had no borrowings under the working capital loans.

Administrative Services Agreement

The Company entered into an Administrative Service Agreement, commencing on the effective date of the IPO through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay the Sponsor a total of $10,000 per month for office space, administrative and support services. The monthly fees will be ceased upon completion of an initial Business Combination or liquidation. For the three and nine months ended September 30, 2023 the Company incurred $30,000 and $90,000, respectively, in fees for these services. The Company accrued $118,387 and $28,387 administrative fees in the accompanying balance sheets as of September 30, 2023 and December 31, 2022, respectively. The Company did not incur any administrative fees for the three and nine months ended September 30, 2022.

Note 6 — Commitments and Contingency

Registration Rights

The holders of the Founder Shares, Private Units (and all underlying securities), and any shares that may be issued upon conversion of working capital loans will be entitled to registration rights pursuant to a registration rights agreement signed on the effective date of IPO. The holders of the majority of these securities are entitled to make up to three demands that the Company register such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which the Founder Shares are to be released from escrow. The holders of a majority of the Private Units and units issued in payment of working capital loans made to the Company can elect to exercise these registration rights at any time commencing on the date that the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters were paid a cash underwriting discount of 1.75% of the gross proceeds of the IPO, or $922,775. In addition, the underwriters are entitled to a deferred fee of 4.00% of the gross proceeds of the IPO, or $2,109,200, which will be paid upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement.

Note 7 — Stockholders’ Equity

Common Stock — The Company is authorized to issue 16,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the common stock are entitled to one vote for each share. As of December 31, 2021, there were 1,437,500 shares of common stock issued and outstanding, of which an aggregate of up to 187,500 Founder Shares are subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full, so that the Initial Stockholders will collectively own 20% of the Company’s issued and outstanding shares after the IPO (assuming the Initial Stockholders do not purchase any Public Shares in the IPO and excluding the Private Units). As a result of the underwriter’s partial exercise of the over-allotment option on October 4, 2022, 119,250 shares of the Founder Shares were forfeited for no consideration on October 7, 2022. As of September 30, 2023 and December 31, 2022, there were 1,662,623 shares of common stock issued and outstanding (excluding 1,913,012 and 5,273,000 shares subject to possible redemption, respectively).

Rights — Each holder of a right will receive one-tenth (1/10) of one share of common stock upon consummation of a Business Combination, even if the holder of such right redeemed all shares held by it in connection with a Business Combination. No fractional shares will be issued upon conversion of the rights. No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares upon consummation of a Business Combination, as the consideration related thereto has been included in the Unit purchase price paid for by investors in the Initial Public Offering. If the Company enters into a definitive agreement for a Business Combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the common stock will receive in the transaction on an as-converted into common stock basis and each holder of a right will be required to affirmatively convert its rights in order to receive one-tenth (1/10) of one share underlying each right (without paying additional consideration). The shares issuable upon conversion of the rights will be freely tradable (except to the extent held by affiliates of the Company).

If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of a Business Combination. Additionally, in no event will the Company be required to net cash settle the rights. Accordingly, holders of the rights might not receive the shares of common stock underlying the rights.

Warrants — Each redeemable warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per share, subject to adjustment as described in this prospectus. The warrants will become exercisable on the later 30 days following the completion of an initial Business Combination and 12 months from the date of this prospectus. The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its best efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the common stock issuable upon exercise of the warrants. Notwithstanding the foregoing, if a registration statement covering the issuance of the common stock issuable upon exercise of the Public Warrants is not effective within a specified period following the closing of the Company’s initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The warrants will expire five years from the closing of the Company’s initial Business Combination at 5:00 p.m., New York City time or earlier upon redemption.

The Company may redeem the outstanding warrants:

●

in whole and not in part;

●

at a price of $0.01 per warrant;

●

upon a minimum of 30 days’ prior written notice of redemption, which the Company refers to as the 30-day redemption period;

●

if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the to the warrant holders.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.

Except as described above, no warrants will be exercisable and the Company will not be obligated to issue common stock unless at the time a holder seeks to exercise such warrant, a prospectus relating to the common stock issuable upon exercise of the warrants is current and the common stock have been registered or qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. Under the terms of the warrant agreement, the Company has agreed to use its best efforts to meet these conditions and to maintain a current prospectus relating to the common stock issuable upon exercise of the warrants until the expiration of the warrants. However, the Company cannot assure that it will be able to do so and, if the Company does not maintain a current prospectus relating to the common stock issuable upon exercise of the warrants, holders will be unable to exercise their warrants and the Company will not be required to settle any such warrant exercise. If the prospectus relating to the common stock issuable upon the exercise of the warrants is not current or if the common stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, the Company will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and the warrants may expire worthless.

The Private Warrants have terms and provisions that are identical to those of the warrants being sold as part of the units in the IPO except that the Private Warrants will be entitled to registration rights. The Private Warrants (including the common stock issuable upon exercise of the Private Warrants) will not be transferable, assignable or salable until 30 days after the completion of our initial business combination except to permitted transferees.

Note 8 — Fair Value Measurements

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

Level 1:	Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2:	Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3:	Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

	September 30, 2023		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Assets
Marketable securities held in Trust Account	$	33,720,333	$	33,720,333	$	—	$	—

	December 31, 2022		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Assets
Marketable securities held in Trust Account	$	53,958,681	$	53,958,681	$	—	$	—

Note 10 — Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were issued. Based on the review, as further disclosed in the footnotes and except as disclosed below, management did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.

On October 4, 2023, the Company paid approximately $13,082,703 to redeemed public stockholders.

On October 26, 2023, the Sponsor loaned the Company $145,000 to be used, in part, for extension deposits and transaction costs related to the Business Combination. The Promissory Note is unsecured, interest-free and due on the date the Company consummates a business combination.

On October 31, 2023, the Company made a deposit of $63,129 to the Trust Account and extended the date the Company has to consummate an initial business combination from November 3, 2023 to December 3, 2023.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this report (this “Quarterly Report”) to “we,” “us” or the “Company” refer to Qomolangma Acquisition Corp. References to our “management” or our “management team” refer to our officers and directors. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report, including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the search for an initial business combination, the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s final prospectus for its initial public offering filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s filings with the SEC can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company incorporated in Delaware on May 6, 2021. We were formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses, which we refer to herein as our “initial business combination.” Our efforts to identify a prospective target business are not limited to any particular industry or geographic region, although we intend to pursue target businesses that are strategically significant in the Asian markets and focus on businesses with a total enterprise value of between $300,000,000 and $500,000,000. We intend to utilize cash derived from the proceeds of our initial public offering (“IPO” as defined below) and the private placement of Private Units, our securities, debt or a combination of cash, securities and debt, in effecting our initial business combination.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete an initial business combination will be successful.

Recent Developments

In connection with the Special Meeting, an aggregate of 2,126,934 shares with redemption value of approximately $22,141,383 (or $10.41 per share) of the Company’s common stock were tendered for redemption.

On September 12, 2023, the Company held a special meeting of stockholders (the “September Special Meeting”). At the September Special Meeting, the stockholders amended the Company’s Amended and Restated Certificate of Incorporation to allow the Company to undertake an initial business combination with an entity or business, with a physical presence, operation, or other significant ties to China (a “China-based Target”) or which may subject the post-business combination business to the laws, regulations and policies of China (including Hong Kong and Macao), or entity or business that conducts operations in China through variable interest entities, or VIEs, pursuant to a series of contractual arrangements with the VIE and its shareholders on one side, and a China-based subsidiary of the China-based Target, on the other side.

On September 26, 2023 and October 31, 2023, the Sponsor made a deposit of $47,277 (which reflects a reduction of $18,377 previously deposited for the September monthly extension fee as a result of the Company’s public shares redeemed on September 12 and applied to the October monthly extension fee of $65,604) and $63,129, respectively, to the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from October 4, 2023 to December 3, 2023.

Results of Operations

We have neither engaged in any operations nor generated any operating revenues to date. Our only activities through September 30, 2023 were organizational activities and those necessary to prepare for our IPO, which is described below, and subsequent to the IPO, identifying a target company for an initial business combination. We do not expect to generate any operating revenues until after the completion of our initial business combination.

We expect to generate non-operating income in the form of interest income on investments held in the Trust Account. We expect that we will incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with searching for, and completing, a Business Combination.

For the three months ended September 30, 2023, we had a net loss of $2,739, which consisted of loss from operations of $351,112 derived from general and administrative expenses of $344,212, franchise tax expense of $6,900, and income tax expense of $90,772 offset by interest earned on investments held in the Trust Account of $439,145. For the three months ended September 30, 2022, we had a net income of $5,014, consisted of formation costs and refund of franchise tax payments.

For the nine months ended September 30, 2023, we had a net loss of $37,519, which consisted of loss from operations of $1,356,343 derived from general and administrative expenses of $1,325,643, franchise tax expense of $30,700 and income tax expense of $342,413, offset by interest earned on investments held in the Trust Account of $1,661,237. For the nine months ended September 30, 2022, we had a net loss of $7,271, all of which consisted of formation costs.

For the nine months ended September 30, 2023, cash balance was decreased by $149,893, which consisted of cash used in operating activities of $545,322 and financing activities of $21,791,383 which was primarily used to pay redeemed public stockholders, offset by cash provided by investing activities of $22,186,812 consisting cash drawn from Trust Account to fund stockholder redemptions and loans from the Sponsor.

For the nine months ended September 30, 2022, cash balance was decreased by $99,301, which consisted of cash used in operating activities of $7,271 and financing activities of $92,030, respectively.

Liquidity, Capital Resources and Going Concern

On October 4, 2022, we completed our initial public offering (“IPO”) of 5,000,000 units (the “Public Units”), at $10.00 per Public Unit, generating gross proceeds of $50,000,000. Each Public Unit consisted of one share of common stock, par value $0.0001, one redeemable warrant and one right to receive one-tenth (1/10) of a share of common stock upon the consummation of an initial business combination. Simultaneously with the closing of the IPO, we completed the sale of 260,500 units (the “Private Units”) in a private placement, at a price of $10.00 per Private Unit, generating gross proceeds of $2,605,000.

We granted the underwriters in the IPO a 45-day option to purchase up to 750,000 additional Public Units to cover over-allotments, if any. On October 4, 2022, the underwriters partially exercised the over-allotment option to purchase 273,000 Units (“Over-Allotment Option Units”) at $10.00 per Unit, which was closed on October 7, 2022 generating total gross proceeds of $2,730,000. On October 7, 2022, simultaneously with the sale of the Over-Allotment Option Units, the Company consummated the private placement of an additional 8,873 Private Units generating gross proceeds of $88,725. Simultaneously with the closing of the IPO, we issued Ladenburg Thalmann & Co., Inc., the underwriter, 75,000 shares of common stock.

Following the IPO and the private placement (including the Over-Allotment Option Units and the Over-Allotment Private Units), a total of $53,520,950 was placed in a trust account located in the United States established for the benefit of the Company’s public stockholders (the “Trust Account”) maintained by American Stock Transfer & Trust Company as a trustee and will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended, and that invest only in direct U.S. government treasury obligations.

We intend to use substantially all of the net proceeds of the IPO and the private placement, including the funds held in the Trust Account, in connection with our initial business combination and to pay our expenses relating thereto, including deferred underwriting discounts and commissions payable to the underwriters in the IPO in an amount equal to 4.0% of the total gross proceeds raised in the IPO upon consummation of our initial business combination. To the extent that our capital stock is used in whole or in part as consideration to effect our initial business combination, the remaining proceeds held in the Trust Account as well as any other net proceeds not expended will be used as working capital to finance the operations of the target business. Such working capital funds could be used in a variety of ways including continuing or expanding the target business’ operations, for strategic acquisitions and for marketing, research and development of existing or new products. Such funds could also be used to repay any operating expenses or finders’ fees which we had incurred prior to the completion of our initial business combination if the funds available to us outside of the Trust Account were insufficient to cover such expenses.

As of September 30, 2023, the Company had $46,617 of cash held outside its Trust Account and a working capital deficit of $1,812,749 (excluding redeemed common stock payable to public stockholders, income tax and franchise tax payable as redemptions and taxes are paid out of the Trust Account). On March 22, June 26, September 12, September 26 and October 26, 2023, the Sponsor loaned the Company $200,000, $240,000, $150,000, $47,227, and $63,129, respectively, to be used, in part, for extension deposits. As a result of the Sponsor’s deposit of $63,129 to the Trust Account on October 31, 2023, the Company has until December 4, 2023 (unless the Company extends the time to complete a Business Combination) to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution.

Off-Balance Sheet Arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2023 and December 31, 2022. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations

Promissory Notes – Related Party

The Company received $155,025 from the Sponsor at the closing of IPO to finance transaction costs in connection with searching for a target business. On October 7, 2022, the Sponsor converted the outstanding balance of $155,025 to the Promissory Note. On March 22, 2023, June 26, 2023, September 12, 2023 and September 26, 2023, the Sponsor loaned the Company $200,000, $240,000, $150,000 and $47,227 (collectively “Promissory Notes”), respectively, to be used, in part, for extension deposits. Each Promissory Note is unsecured, interest-free and due on the date the Company consummates a business combination. As of September 30, 2023 and December 31, 2022, $792,252 and $155,025 were outstanding under the Promissory Notes, respectively.

Administrative Services Agreement

We have entered into an administrative services agreement pursuant to which we will pay the Sponsor a total of $10,000 per month (subject to deferral as described herein) for office space, utilities, secretarial and administrative support services. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees. For the three and nine months ended September 30, 2023 the Company incurred $30,000 and $90,000, respectively, in fees for these services. We accrued $118,387 and $28,387 administrative fees in the accompanying balance sheets as of September 30, 2023 and December 31, 2022, respectively.

Registration Rights

The holders of the founder shares, private placement units, and units that may be issued on conversion of working capital loans (and any securities underlying the private placement units and the working capital loans) are entitled to registration rights pursuant to a registration rights agreement signed on the effective date of the IPO requiring us to register such securities for resale. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our completion of our initial business combination and rights to require us to register for resale such securities pursuant to Rule 415 under the Securities Act. We will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

Critical Accounting Policies

The preparation of unaudited condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

Common Stock Subject to Possible Redemption

We account for our common stock subject to possible conversion in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. Our common stock features certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of our condensed balance sheets. We made a policy election in accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in accumulated deficit over an expected 9-month period leading up to a Business Combination.

Warrants

Net Income (Loss) Per Share

The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net loss less any dividends paid. We then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any re-measurement of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public shareholders.

Recent accounting pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 for the Company and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to make disclosures under this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the fiscal quarter ended September 30, 2023, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that during the period covered by this report, our disclosure controls and procedures were effective.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control Over Financial Reporting

During the quarter ended September 30, 2023, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II – Other Information

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

As a smaller reporting company, we are not required to make disclosures under this Item. We have provided a comprehensive list of risk factors in the final prospectus for our IPO as filed with the SEC on October 3, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On October 4, 2022, we consummated the IPO of 5,000,000 Public Units, each Public Unit consisting of one share of common stock, one redeemable warrant and one right, for $10.00 per Public Unit, generating gross proceeds of $50,000,000. Each warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per share, subject to adjustment. Each right entitles the holder thereof to receive one-tenth (1/10) of a share of common stock upon the consummation of an initial business combination. We had granted the underwriters in the IPO a 45-day option to purchase up to 750,000 additional Public Units to cover over-allotments.

Subsequently, the underwriter partially exercised the over-allotment option in full and, on October 7, 2022, purchased 273,000 Public Units at an offering price of $10.00 per Public Unit for an aggregate purchase price of $2,730,000. The securities in the IPO, including the exercise by the underwriters of the over-allotment option, were registered under the Securities Act on a registration statement on Form S-1 (No. 333-265447). The SEC declared the registration statement effective on September 29, 2022.

On October 4, 2022, simultaneously with the closing of the IPO, we sold an aggregate of 260,500 Private Units in a private placement with the Sponsor, at a price of $10.00 per Private Unit, generating gross proceeds of $2,605,000. The Private Units are identical to the units sold in the IPO, except that (a) the Private Units and underlying securities will not be transferable, assignable or salable until the consummation of our initial business combination, except to permitted transferees, and (b) the private warrants, so long as they are held by the initial purchasers or their permitted transferees, (i) will not be redeemable by us, (ii) may be exercised by the holders on a cashless basis, and (iii) will be entitled to registration rights.

On October 7, 2022, simultaneously with the closing of the exercise of the over-allotment option, we consummated the sale of an additional aggregate of 8,873 Private Units in a private placement to the Sponsor, at a purchase price of $10.00 per Private Unit, generating gross proceeds of $88,725. The Private Units were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

A total of $53,520,950 of the net proceeds from the sale of the Public Units in the IPO and the private placement of the Private Units on October 4, 2022 and October 7, 2022 were deposited in a trust account established for the benefit of the Company’s public stockholders at Bank of America, N.A. maintained by American Stock Transfer & Trust Company, acting as trustee.

For a description of the use of the proceeds generated in our IPO, see Part I, Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations of this Quarterly Report.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report.

Exhibit No.		Description
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)

*	Filed herewith.

Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	QOMOLANGMA ACQUISITION CORP.

Date: November 13, 2023	By:	/s/ Jonathan P. Myers
	Name:	Jonathan P. Myers
	Title:	Chief Executive Officer (Principal Executive Officer)

Date: November 13, 2023	By:	/s/ Hao Shen
	Name:	Hao Shen
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

2904816 4448538 0.05 0.52 1250000 1250000 1662623 1662623 0.00 0.01 0.09 1.41 1250000 1662623 2904816 0.00 0.05 0.09 1250000 1662623 4448538 0.01 0.52 1.41 P5Y false --12-31 Q3 0001894210 0001894210 2023-01-01 2023-09-30 0001894210 qomo:UnitsMember 2023-01-01 2023-09-30 0001894210 qomo:CommonStocksMember 2023-01-01 2023-09-30 0001894210 qomo:WarrantsMember 2023-01-01 2023-09-30 0001894210 qomo:RightMember 2023-01-01 2023-09-30 0001894210 2023-11-13 0001894210 2023-09-30 0001894210 2022-12-31 0001894210 us-gaap:RelatedPartyMember 2023-09-30 0001894210 us-gaap:RelatedPartyMember 2022-12-31 0001894210 2023-07-01 2023-09-30 0001894210 2022-07-01 2022-09-30 0001894210 2022-01-01 2022-09-30 0001894210 qomo:RedeemableCommonStockMember 2023-07-01 2023-09-30 0001894210 qomo:RedeemableCommonStockMember 2022-07-01 2022-09-30 0001894210 qomo:RedeemableCommonStockMember 2023-01-01 2023-09-30 0001894210 qomo:RedeemableCommonStockMember 2022-01-01 2022-09-30 0001894210 qomo:NonredeemableCommonStockMember 2023-07-01 2023-09-30 0001894210 qomo:NonredeemableCommonStockMember 2022-07-01 2022-09-30 0001894210 qomo:NonredeemableCommonStockMember 2023-01-01 2023-09-30 0001894210 qomo:NonredeemableCommonStockMember 2022-01-01 2022-09-30 0001894210 us-gaap:CommonStockMember 2022-12-31 0001894210 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001894210 us-gaap:RetainedEarningsMember 2022-12-31 0001894210 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001894210 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001894210 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001894210 2023-01-01 2023-03-31 0001894210 us-gaap:CommonStockMember 2023-03-31 0001894210 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001894210 us-gaap:RetainedEarningsMember 2023-03-31 0001894210 2023-03-31 0001894210 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001894210 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001894210 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001894210 2023-04-01 2023-06-30 0001894210 us-gaap:CommonStockMember 2023-06-30 0001894210 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001894210 us-gaap:RetainedEarningsMember 2023-06-30 0001894210 2023-06-30 0001894210 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001894210 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001894210 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001894210 us-gaap:CommonStockMember 2023-09-30 0001894210 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001894210 us-gaap:RetainedEarningsMember 2023-09-30 0001894210 us-gaap:CommonStockMember 2021-12-31 0001894210 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001894210 us-gaap:RetainedEarningsMember 2021-12-31 0001894210 2021-12-31 0001894210 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001894210 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001894210 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001894210 2022-01-01 2022-03-31 0001894210 us-gaap:CommonStockMember 2022-03-31 0001894210 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001894210 us-gaap:RetainedEarningsMember 2022-03-31 0001894210 2022-03-31 0001894210 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001894210 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001894210 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001894210 2022-04-01 2022-06-30 0001894210 us-gaap:CommonStockMember 2022-06-30 0001894210 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001894210 us-gaap:RetainedEarningsMember 2022-06-30 0001894210 2022-06-30 0001894210 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001894210 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001894210 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001894210 us-gaap:CommonStockMember 2022-09-30 0001894210 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001894210 us-gaap:RetainedEarningsMember 2022-09-30 0001894210 2022-09-30 0001894210 srt:MinimumMember 2022-01-01 2022-09-30 0001894210 srt:MaximumMember 2022-01-01 2022-09-30 0001894210 us-gaap:IPOMember 2022-10-04 2022-10-04 0001894210 qomo:PublicUnitsMember us-gaap:IPOMember 2022-10-04 0001894210 us-gaap:IPOMember 2023-01-01 2023-09-30 0001894210 qomo:PrivateUnitsMember 2023-09-30 0001894210 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-09-30 0001894210 us-gaap:OverAllotmentOptionMember 2022-10-04 2022-10-04 0001894210 qomo:PublicUnitsMember 2022-10-04 0001894210 us-gaap:OverAllotmentOptionMember 2022-10-07 2022-10-07 0001894210 us-gaap:PrivatePlacementMember 2023-01-01 2023-09-30 0001894210 2022-10-07 2022-10-07 0001894210 2022-10-04 0001894210 2022-10-07 0001894210 qomo:BusinessCombinationMember 2023-01-01 2023-09-30 0001894210 us-gaap:CommonStockMember 2023-09-30 0001894210 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001894210 srt:MinimumMember us-gaap:CommonStockMember 2023-09-30 0001894210 qomo:BusinessCombinationMember 2023-09-30 0001894210 srt:MaximumMember 2023-09-30 0001894210 us-gaap:DepositsMember us-gaap:SubsequentEventMember 2023-10-31 0001894210 2023-03-22 0001894210 2023-06-26 0001894210 2023-09-12 0001894210 2023-09-26 0001894210 us-gaap:SubsequentEventMember 2023-10-26 0001894210 2022-08-16 2022-08-16 0001894210 qomo:PublicUnitsMember 2023-01-01 2023-06-30 0001894210 us-gaap:SubsequentEventMember 2023-10-05 2023-10-05 0001894210 qomo:RedeemableShareMember 2023-07-01 2023-09-30 0001894210 qomo:NonRedeemableSharesMember 2023-07-01 2023-09-30 0001894210 qomo:RedeemableShareMember 2022-07-01 2022-09-30 0001894210 qomo:NonRedeemableSharesMember 2022-07-01 2022-09-30 0001894210 qomo:RedeemableShareMember 2023-01-01 2023-09-30 0001894210 qomo:NonRedeemableSharesMember 2023-01-01 2023-09-30 0001894210 qomo:RedeemableShareMember 2022-01-01 2022-09-30 0001894210 qomo:NonRedeemableSharesMember 2022-01-01 2022-09-30 0001894210 2022-01-01 2022-12-31 0001894210 2022-10-04 2022-10-04 0001894210 us-gaap:OverAllotmentOptionMember 2022-10-07 0001894210 us-gaap:NoteWarrantMember 2023-09-30 0001894210 qomo:SponsorMember 2023-09-30 0001894210 qomo:SponsorMember us-gaap:PrivatePlacementMember 2023-09-30 0001894210 qomo:PrivateWarrantsMember 2023-09-30 0001894210 2021-09-25 0001894210 2021-09-25 2021-09-25 0001894210 qomo:FounderSharesMember 2021-09-25 0001894210 us-gaap:OverAllotmentOptionMember 2023-09-30 0001894210 2022-10-01 2022-10-04 0001894210 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-09-30 0001894210 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-01-01 2023-09-30 0001894210 2021-09-01 2021-09-05 0001894210 2022-10-01 2022-10-07 0001894210 qomo:UnderwritingAgreementMember 2023-01-01 2023-09-30 0001894210 us-gaap:CommonStockMember 2021-12-31 0001894210 2021-01-01 2021-12-31 0001894210 us-gaap:WarrantMember 2023-09-30 0001894210 us-gaap:FairValueInputsLevel1Member 2023-09-30 0001894210 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001894210 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001894210 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001894210 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001894210 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001894210 us-gaap:SubsequentEventMember 2023-10-04 2023-10-04 0001894210 us-gaap:SubsequentEventMember 2023-10-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Exhibit 31.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302

I, Jonathan P. Myers, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Qomolangma Acquisition Corp. for the quarter ended September 30, 2023;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) [Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2023	By:	/s/ Jonathan P. Myers
		Jonathan P. Myers
		Chairman, President and Chief Executive Officer (Principal Executive Officer)

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302

I, Hao Shen, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Qomolangma Acquisition Corp. for the quarter ended September 30, 2023;

(b) [Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2023	By:	/s/ Hao Shen
		Hao Shen
		Chief Financial Officer (Principal Financial and Accounting Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Qomolangma Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ending September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chairman, President and Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2023	By:	/s/ Jonathan P. Myers
		Jonathan P. Myers
		Chairman, President and Chief Executive Officer

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Qomolangma Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ending September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2023

By:

/s/ Hao Shen

Hao Shen

Chief Financial Officer (Principal Financial and Accounting Officer)

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2023	Nov. 13, 2023
Document Information Line Items
Entity Registrant Name	Qomolangma Acquisition Corp.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		3,575,635
Amendment Flag	false
Entity Central Index Key	0001894210
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	true
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-41518
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-3733656
Entity Address, Address Line One	1178 Broadway
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10010
City Area Code	(646)
Local Phone Number	791-7587
Entity Interactive Data Current	Yes
Units
Document Information Line Items
Trading Symbol	QOMOU
Title of 12(b) Security	Units
Security Exchange Name	NASDAQ
Common Stock
Document Information Line Items
Trading Symbol	QOMO
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Warrants
Document Information Line Items
Trading Symbol	QOMOW
Title of 12(b) Security	Warrants
Security Exchange Name	NASDAQ
Rights
Document Information Line Items
Trading Symbol	QOMOR
Title of 12(b) Security	Rights
Security Exchange Name	NASDAQ

Condensed Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash	$ 46,617	$ 196,510
Prepaid expenses	122,900	235,476
Total Current Assets	169,517	431,986
Investments held in Trust Account	33,720,333	53,958,681
Total Assets	33,889,850	54,390,667
Current Liabilities
Accrued expenses	719,385	96,212
Accrued expenses – related party	118,387	28,387
Franchise tax payable	30,700	45,428
Income tax payable	394,514	46,115
Excise tax liability	352,241
Redeemed common stock payable to public stockholders	13,082,703
Total Current Liabilities	15,490,182	371,167
Deferred tax liability	30,178	36,164
Deferred underwriting fee payable	2,109,200	2,109,200
Total Liabilities	17,629,560	2,516,531
Commitments and Contingencies
Common stock subject to possible redemption, $0.0001 par value; 16,000,000 shares authorized; 1,913,012 shares and 5,273,000 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively, at redemption value of $10.57 and $10.22 at September 30, 2023 and December 31, 2022, respectively	20,181,740	46,828,833
Stockholders’ Equity (Deficit)
Common stock, $0.0001 par value; 16,000,000 shares authorized; 1,662,623 shares issued and outstanding (excluding 1,913,012 shares 5,273,000 shares subject to possible redemption at September 30, 2023 and December 31, 2022, respectively)	166	166
Additional paid-in capital		4,914,221
(Accumulated deficit) Retained earnings	(3,921,616)	130,916
Total Stockholders’ Equity (Deficit)	(3,921,450)	5,045,303
Total Liabilities, Temporary Equity, and Stockholders’ Equity	33,889,850	54,390,667
Related Party
Current Liabilities
Promissory note - related party	$ 792,252	$ 155,025

Condensed Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock subject to possible redemption, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock subject to possible redemption, shares authorized	16,000,000	16,000,000
Common stock subject to possible redemption, shares issued	1,913,012	5,273,000
Common stock subject to possible redemption, shares outstanding	1,913,012	5,273,000
Common stock subject to possible redemption, par value (in Dollars per share)	$ 10.57	$ 10.22
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	16,000,000	16,000,000
Common stock, shares issued	1,662,623	1,662,623
Common stock, shares outstanding	1,662,623	1,662,623

Unaudited Condensed Statements of Operations - USD ($)

3 Months Ended

9 Months Ended

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

General and administrative expenses

$ 344,212

$ 122

$ 1,325,643

$ 7,271

Franchise tax expenses

6,900

(5,136)

30,700

Income (loss) from operations

(351,112)

5,014

(1,356,343)

(7,271)

Interest earned on investments held in Trust Account

439,145

1,661,237

Income (loss) before income taxes

88,033

5,014

304,894

(7,271)

Income taxes provision

(90,772)

(342,413)

Net income (loss)

$ (2,739)

$ 5,014

$ (37,519)

$ (7,271)

Redeemable common stock

Basic weighted average shares outstanding (in Shares)

2,904,816

4,448,538

Basic net income (loss) per share (in Dollars per share)

$ 0.05

$ 0.52

Non-redeemable common stock

Basic weighted average shares outstanding (in Shares)

1,662,623

1,250,000

^[1]

1,662,623

1,250,000

^[1]

Basic net income (loss) per share (in Dollars per share)

$ (0.09)

$ 0

$ (1.41)

$ (0.01)

[1]

Unaudited Condensed Statements of Operations (Parentheticals) - $ / shares

3 Months Ended

9 Months Ended

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Redeemable common stock

Diluted weighted average shares outstanding

2,904,816

4,448,538

Diluted net income (loss) per share

$ 0.05

$ 0.52

Non-redeemable common stock

Diluted weighted average shares outstanding

1,662,623

1,250,000

^[1]

1,662,623

1,250,000

^[1]

Diluted net income (loss) per share

$ (0.09)

$ 0.00

$ (1.41)

$ (0.01)

[1]

Unaudited Condensed Statements of Changes in Stockholders’ Equity (Deficit) - USD ($)

Common Stock

Additional Paid-In Capital

Accumulated Deficit

Total

Balance at Dec. 31, 2021

$ 144

$ 24,856

$ (3,935)

$ 21,065

Balance (in Shares) at Dec. 31, 2021

1,437,500

^[1]

1,437,500

Net income (loss)

(7,318)

$ (7,318)

Balance at Mar. 31, 2022

$ 144

24,856

(11,253)

13,747

Balance (in Shares) at Mar. 31, 2022

^[1]

1,437,500

Balance at Dec. 31, 2021

$ 144

24,856

(3,935)

$ 21,065

Balance (in Shares) at Dec. 31, 2021

1,437,500

^[1]

1,437,500

Net income (loss)

$ (7,271)

Balance at Sep. 30, 2022

$ 144

24,856

(11,206)

13,794

Balance (in Shares) at Sep. 30, 2022

^[1]

1,437,500

Balance at Mar. 31, 2022

$ 144

24,856

(11,253)

13,747

Balance (in Shares) at Mar. 31, 2022

^[1]

1,437,500

Net income (loss)

(4,967)

Balance at Jun. 30, 2022

$ 144

24,856

(16,220)

8,780

Balance (in Shares) at Jun. 30, 2022

^[1]

1,437,500

Net income (loss)

5,014

Balance at Sep. 30, 2022

$ 144

24,856

(11,206)

13,794

Balance (in Shares) at Sep. 30, 2022

^[1]

1,437,500

Balance at Dec. 31, 2022

$ 166

4,914,221

130,916

$ 5,045,303

Balance (in Shares) at Dec. 31, 2022

1,662,623

Accretion of common stock to redemption value

(3,802,141)

$ (3,802,141)

Net income (loss)

(224,171)

Balance at Mar. 31, 2023

$ 166

1,112,080

(93,255)

1,018,991

Balance (in Shares) at Mar. 31, 2023

1,662,623

Balance at Dec. 31, 2022

$ 166

4,914,221

130,916

$ 5,045,303

Balance (in Shares) at Dec. 31, 2022

1,662,623

Net income (loss)

$ (37,519)

Balance at Sep. 30, 2023

$ 166

(3,921,616)

$ (3,921,450)

Balance (in Shares) at Sep. 30, 2023

1,662,623

Balance at Mar. 31, 2023

$ 166

1,112,080

(93,255)

$ 1,018,991

Balance (in Shares) at Mar. 31, 2023

1,662,623

Accretion of common stock to redemption value

(1,112,080)

(3,274,072)

(4,386,152)

Excise tax liability

(221,414)

Net income (loss)

189,391

Balance at Jun. 30, 2023

$ 166

(3,399,350)

(3,399,184)

Balance (in Shares) at Jun. 30, 2023

1,662,623

Accretion of common stock to redemption value

(388,700)

Excise tax liability

(130,827)

Net income (loss)

(2,739)

Balance at Sep. 30, 2023

$ 166

$ (3,921,616)

$ (3,921,450)

Balance (in Shares) at Sep. 30, 2023

1,662,623

[1]

Unaudited Condensed Statements of Cash Flows - USD ($)	9 Months Ended
Unaudited Condensed Statements of Cash Flows - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (37,519)	$ (7,271)
Adjustments to reconcile net cash used in operating activities:
Interest earned on investments held in Trust Account	(1,661,237)
Deferred income tax	(5,986)
Changes in current assets and current liabilities:
Prepaid expenses	112,576
Accrued expenses	623,173
Accrued expenses – related party	90,000
Franchise tax payable	(14,728)
Income tax payable	348,399
Net cash used in operating activities	(545,322)	(7,271)
Cash Flows from Investing Activities:
Cash withdrawal from Trust Account to pay franchise tax	45,429
Cash withdrawal from Trust Account to pay public stockholder redemptions	22,141,383
Net cash provided by investing activities	22,186,812
Cash Flows from Financing Activities:
Repayment to related party advances		(1,500)
Proceeds from issuance of promissory note to related party	350,000
Payment of public stockholder redemptions	(22,141,383)
Payment of deferred offering costs		(90,530)
Net cash used in financing activities	(21,791,383)	(92,030)
Net change in cash	(149,893)	(99,301)
Cash, beginning of the period	196,510	154,565
Cash, end of the period	46,617	55,264
Supplemental Disclosure of Non-cash Investing and Financing Activities
Deferred offering costs in accrued offering costs		65,000
Excise tax liability accrued for common stock redemption	352,241
Accretion of Common stock to redemption value	8,576,993
Redeemed common stock payable to public stockholders	13,082,703
Extension fee deposited into Trust Account by the Sponsor through issuance of Promissory Note	$ 287,227

Description of Organization and Business Operations

9 Months Ended

Sep. 30, 2023

Description of Organization and Business Operations [Abstract]

Description of Organization and Business Operations

Note 1 — Description of Organization and Business Operations

The Company’s sponsor is Qomolangma Investments LLC (the “Sponsor”), a Delaware limited liability company.

Liquidity, Capital Resources and Going Concern

Risks and Uncertainties

Inflation Reduction Act of 2022

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2023

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 — Summary of Significant Accounting Policies

Basis of Presentation

Emerging Growth Company

Use of Estimates

Cash and Cash Equivalents

Investments Held in Trust Account

Income Taxes

The Company has identified the United States as its only “major” tax jurisdiction.

Net Income (Loss) Per Share

The net income (loss) per share presented in the unaudited condensed statements of operations is based on the following:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2023			2022		2023			2022
Net income (loss)	$	(2,739	)	$	5,014	$	(37,519	)	$	(7,271	)
Accretion of common stock to redemption value		(388,700	)		—		(8,576,993	)		—
Net income (loss) including accretion of common stock to redemption value	$	(391,439	)	$	5,014	$	(8,614,512	)	$	(7,271	)

	Three Months Ended September 30, 2023						Nine Months Ended September 30, 2022
	Redeemable share			Non- redeemable shares			Redeemable shares		Non- redeemable shares
Basic and diluted net income/(loss) per share:
Numerator:
Allocation of net income (loss) including accretion of common stock	$	(248,949	)	$	(142,490	)	$	—	$	5,014
Accretion of common stock to redemption value		388,700			—			—		—
Allocation of net income (loss)	$	139,751		$	(142,490	)	$	—	$	5,014

Denominator:
Basic and diluted weighted average shares outstanding		2,904,816			1,662,623			—		1,250,000
Basic and diluted net income (loss) per share	$	0.05		$	(0.09	)	$	—	$	0.00

	Nine Months Ended September 30, 2023						Nine Months Ended September 30, 2022
	Redeemable share			Non- redeemable shares			Redeemable shares		Non- redeemable shares
Basic and diluted net income/(loss) per share:
Numerator:
Allocation of net income (loss) including accretion of common stock	$	(6,270,820	)	$	(2,343,692	)	$	—	$	(7,271	)
Accretion of common stock to redemption value		8,576,993			—			—		—
Allocation of net income (loss)	$	2,306,173		$	(2,343,692	)	$	—	$	(7,271	)

Denominator:
Basic and diluted weighted average shares outstanding		4,448,538			1,662,623			—		1,250,000
Basic and diluted net income (loss) per share	$	0.52		$	(1.41	)	$	—	$	(0.01	)

Concentration of Credit Risk

Fair Value of Financial Instruments

The fair value hierarchy is categorized into three levels based on the inputs as follows:

Level 1

Level 2

Level 3

Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Warrants

Common Stock Subject to Possible Redemption

At December 31, 2022 and September 30, 2023, the amounts of common stock subject to possible redemption reflected in the balance sheets are reconciled in the following table:

Gross proceeds	$	52,730,000
Less:
Proceeds allocated to public warrants		(3,532,910	)
Proceeds allocated to public rights		(1,845,550	)
Allocation of offering costs related to redeemable shares		(3,932,347	)
Plus:
Accretion of carrying value to redemption value		3,409,640
Common stock subject to possible redemption - December 31, 2022		46,828,833
Plus:
Accretion of carrying value to redemption value – nine months ended September 30, 2023		8,576,993
Redeemed public stockholders ⁽¹⁾		(35,224,086	)
Common stock subject to possible redemption - September 30, 2023	$	20,181,740

(1)	Includes $13,082,703 payment to redeemed public stockholders which was made on October 5, 2023.

Reclassification of Prior Year Presentation

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Initial Public Offering

9 Months Ended

Sep. 30, 2023

Initial Public Offering [Abstract]

Initial Public Offering

Note 3 — Initial Public Offering

Private Placement

9 Months Ended

Sep. 30, 2023

Private Placement [Abstract]

Private Placement

Note 4 — Private Placement

Related Party Transactions

9 Months Ended

Sep. 30, 2023

Related Party Transactions

Note 5 — Related Party Transactions

Founder Shares

Promissory Note — Related Party

As of September 30, 2023 and December 31, 2022, $792,252 and $155,025 were outstanding under the Promissory Notes, respectively.

Related Party Loans

As of September 30, 2023 and December 31, 2022, the Company had no borrowings under the working capital loans.

Administrative Services Agreement

Commitments and Contingency

9 Months Ended

Sep. 30, 2023

Commitments and Contingency [Abstract]

Commitments and Contingency

Note 6 — Commitments and Contingency

Registration Rights

Underwriting Agreement

Stockholders' Equity

9 Months Ended

Sep. 30, 2023

Stockholders' Equity [Abstract]

Stockholders' Equity

Note 7 — Stockholders’ Equity

The Company may redeem the outstanding warrants:

●

in whole and not in part;

●

at a price of $0.01 per warrant;

●

upon a minimum of 30 days’ prior written notice of redemption, which the Company refers to as the 30-day redemption period;

●

Fair Value Measurements

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 8 — Fair Value Measurements

Level 1:	Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2:	Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3:	Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

	September 30, 2023		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Assets
Marketable securities held in Trust Account	$	33,720,333	$	33,720,333	$	—	$	—

	December 31, 2022		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Assets
Marketable securities held in Trust Account	$	53,958,681	$	53,958,681	$	—	$	—

Subsequent Events

9 Months Ended

Sep. 30, 2023

Subsequent Events [Abstract]

Subsequent Events

Note 10 — Subsequent Events

On October 4, 2023, the Company paid approximately $13,082,703 to redeemed public stockholders.

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2023

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Emerging Growth Company

Emerging Growth Company

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Investments Held in Trust Account

Investments Held in Trust Account

Income Taxes

Income Taxes

The Company has identified the United States as its only “major” tax jurisdiction.

Net Income (Loss) Per Share

Net Income (Loss) Per Share

The net income (loss) per share presented in the unaudited condensed statements of operations is based on the following:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2023			2022		2023			2022
Net income (loss)	$	(2,739	)	$	5,014	$	(37,519	)	$	(7,271	)
Accretion of common stock to redemption value		(388,700	)		—		(8,576,993	)		—
Net income (loss) including accretion of common stock to redemption value	$	(391,439	)	$	5,014	$	(8,614,512	)	$	(7,271	)

	Three Months Ended September 30, 2023						Nine Months Ended September 30, 2022
	Redeemable share			Non- redeemable shares			Redeemable shares		Non- redeemable shares
Basic and diluted net income/(loss) per share:
Numerator:
Allocation of net income (loss) including accretion of common stock	$	(248,949	)	$	(142,490	)	$	—	$	5,014
Accretion of common stock to redemption value		388,700			—			—		—
Allocation of net income (loss)	$	139,751		$	(142,490	)	$	—	$	5,014

Denominator:
Basic and diluted weighted average shares outstanding		2,904,816			1,662,623			—		1,250,000
Basic and diluted net income (loss) per share	$	0.05		$	(0.09	)	$	—	$	0.00

	Nine Months Ended September 30, 2023						Nine Months Ended September 30, 2022
	Redeemable share			Non- redeemable shares			Redeemable shares		Non- redeemable shares
Basic and diluted net income/(loss) per share:
Numerator:
Allocation of net income (loss) including accretion of common stock	$	(6,270,820	)	$	(2,343,692	)	$	—	$	(7,271	)
Accretion of common stock to redemption value		8,576,993			—			—		—
Allocation of net income (loss)	$	2,306,173		$	(2,343,692	)	$	—	$	(7,271	)

Denominator:
Basic and diluted weighted average shares outstanding		4,448,538			1,662,623			—		1,250,000
Basic and diluted net income (loss) per share	$	0.52		$	(1.41	)	$	—	$	(0.01	)

Concentration of Credit Risk

Concentration of Credit Risk

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The fair value hierarchy is categorized into three levels based on the inputs as follows:

Level 1

Level 2

Level 3

Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Warrants

Warrants

Common Stock Subject to Possible Redemption

Common Stock Subject to Possible Redemption

At December 31, 2022 and September 30, 2023, the amounts of common stock subject to possible redemption reflected in the balance sheets are reconciled in the following table:

Gross proceeds	$	52,730,000
Less:
Proceeds allocated to public warrants		(3,532,910	)
Proceeds allocated to public rights		(1,845,550	)
Allocation of offering costs related to redeemable shares		(3,932,347	)
Plus:
Accretion of carrying value to redemption value		3,409,640
Common stock subject to possible redemption - December 31, 2022		46,828,833
Plus:
Accretion of carrying value to redemption value – nine months ended September 30, 2023		8,576,993
Redeemed public stockholders ⁽¹⁾		(35,224,086	)
Common stock subject to possible redemption - September 30, 2023	$	20,181,740

(1)	Includes $13,082,703 payment to redeemed public stockholders which was made on October 5, 2023.

Reclassification of Prior Year Presentation

Reclassification of Prior Year Presentation

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2023

Summary of Significant Accounting Policies [Abstract]

Schedule of Condensed Statement of Operations

The net income (loss) per share presented in the unaudited condensed statements of operations is based on the following:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2023			2022		2023			2022
Net income (loss)	$	(2,739	)	$	5,014	$	(37,519	)	$	(7,271	)
Accretion of common stock to redemption value		(388,700	)		—		(8,576,993	)		—
Net income (loss) including accretion of common stock to redemption value	$	(391,439	)	$	5,014	$	(8,614,512	)	$	(7,271	)

Schedule of Basic and Diluted Net Income (Loss) Per Common Stock

	Three Months Ended September 30, 2023						Nine Months Ended September 30, 2022
	Redeemable share			Non- redeemable shares			Redeemable shares		Non- redeemable shares
Basic and diluted net income/(loss) per share:
Numerator:
Allocation of net income (loss) including accretion of common stock	$	(248,949	)	$	(142,490	)	$	—	$	5,014
Accretion of common stock to redemption value		388,700			—			—		—
Allocation of net income (loss)	$	139,751		$	(142,490	)	$	—	$	5,014

Denominator:
Basic and diluted weighted average shares outstanding		2,904,816			1,662,623			—		1,250,000
Basic and diluted net income (loss) per share	$	0.05		$	(0.09	)	$	—	$	0.00

	Nine Months Ended September 30, 2023						Nine Months Ended September 30, 2022
	Redeemable share			Non- redeemable shares			Redeemable shares		Non- redeemable shares
Basic and diluted net income/(loss) per share:
Numerator:
Allocation of net income (loss) including accretion of common stock	$	(6,270,820	)	$	(2,343,692	)	$	—	$	(7,271	)
Accretion of common stock to redemption value		8,576,993			—			—		—
Allocation of net income (loss)	$	2,306,173		$	(2,343,692	)	$	—	$	(7,271	)

Denominator:
Basic and diluted weighted average shares outstanding		4,448,538			1,662,623			—		1,250,000
Basic and diluted net income (loss) per share	$	0.52		$	(1.41	)	$	—	$	(0.01	)

Schedule of Common Stock Subject to Possible Redemption

At December 31, 2022 and September 30, 2023, the amounts of common stock subject to possible redemption reflected in the balance sheets are reconciled in the following table:

Gross proceeds	$	52,730,000
Less:
Proceeds allocated to public warrants		(3,532,910	)
Proceeds allocated to public rights		(1,845,550	)
Allocation of offering costs related to redeemable shares		(3,932,347	)
Plus:
Accretion of carrying value to redemption value		3,409,640
Common stock subject to possible redemption - December 31, 2022		46,828,833
Plus:
Accretion of carrying value to redemption value – nine months ended September 30, 2023		8,576,993
Redeemed public stockholders ⁽¹⁾		(35,224,086	)
Common stock subject to possible redemption - September 30, 2023	$	20,181,740

(1)	Includes $13,082,703 payment to redeemed public stockholders which was made on October 5, 2023.

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of Company’s Assets that are Measured at Fair Value on a Recurring Basis

	September 30, 2023		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Assets
Marketable securities held in Trust Account	$	33,720,333	$	33,720,333	$	—	$	—

	December 31, 2022		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Assets
Marketable securities held in Trust Account	$	53,958,681	$	53,958,681	$	—	$	—

Description of Organization and Business Operations (Details) - USD ($)				6 Months Ended	9 Months Ended		12 Months Ended
	Oct. 07, 2022	Oct. 04, 2022	Aug. 16, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Oct. 31, 2023	Oct. 26, 2023	Sep. 26, 2023	Sep. 12, 2023	Jun. 26, 2023	Mar. 22, 2023
Description of Organization and Business Operations (Details) [Line Items]
Public share (in Dollars per share)		$ 10
Gross proceeds		$ 50,000,000			$ 2,109,200		$ 52,730,000
Transaction costs					4,222,030
Underwriting fees					875,000
Deferred underwriting fees					2,000,000
Offering costs					$ 1,347,030
Public share per month (in Shares)	53,520,950
Public share (in Dollars per share)	$ 10.15	$ 10.15
Maturity days					185 days
Trust account description					Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test.
Outstanding voting securities percentage					50.00%
Trust account per share (in Dollars per share)					$ 10.15
Tangible assets					$ 5,000,001
Obligation, percentage					100.00%
Deposit into trust account					$ 174,009
Public per share (in Dollars per share)					$ 0.033
Aggregate shares (in Shares)					1,233,054
Redemption value					$ 13,082,703
Redemption per share (in Dollars per share)					$ 10.57		$ 10.22
Deposit to trust account										$ 63,129
Per share value of the assets (in Dollars per share)					10.15
Per public share (in Dollars per share)					$ 10.15
Cash					$ 46,617
Working capital deficit					1,812,748
Sponsor loaned										$ 47,227	$ 150,000	$ 240,000	$ 200,000
U.S. federal excise tax percentage			1.00%
Excise tax percentage			1.00%
Business Combination [Member]
Description of Organization and Business Operations (Details) [Line Items]
Deposit into trust account					$ 80,000
Public per share (in Dollars per share)					$ 0.033
Deposit to trust account					$ 240,000
Minimum [Member]
Description of Organization and Business Operations (Details) [Line Items]
Total enterprise value						$ 300,000,000
Maximum [Member]
Description of Organization and Business Operations (Details) [Line Items]
Total enterprise value						$ 500,000,000
Redemption per share (in Dollars per share)					$ 10.61
IPO [Member]
Description of Organization and Business Operations (Details) [Line Items]
Sale of stock units (in Shares)		5,000,000			260,500
Gross proceeds		$ 50,000,000			$ 2,605,000
Public share per month (in Shares)		53,520,950
Over-Allotment Option [Member]
Description of Organization and Business Operations (Details) [Line Items]
Gross proceeds	$ 2,730,000
Public units					750,000
Purchased public units (in Shares)		273,000
Private Placement [Member]
Description of Organization and Business Operations (Details) [Line Items]
Gross proceeds					$ 88,725
Additional private units (in Shares)					8,873
Common Stock [Member]
Description of Organization and Business Operations (Details) [Line Items]
Aggregate shares (in Shares)					2,126,934
Redemption value					$ 22,141,383
Common Stock [Member] \| Minimum [Member]
Description of Organization and Business Operations (Details) [Line Items]
Redemption per share (in Dollars per share)					$ 10.41
Subsequent Event [Member]
Description of Organization and Business Operations (Details) [Line Items]
Transaction costs									$ 145,000
Deposit to trust account								$ 63,129
Sponsor loaned									$ 145,000
Subsequent Event [Member] \| Deposits
Description of Organization and Business Operations (Details) [Line Items]
Deposit to trust account								$ 63,129
Public Units [Member]
Description of Organization and Business Operations (Details) [Line Items]
Public share (in Dollars per share)		$ 10
Exercise tax liability				$ 352,241
Public Units [Member] \| IPO [Member]
Description of Organization and Business Operations (Details) [Line Items]
Public share (in Dollars per share)		$ 10
Private Units [Member]
Description of Organization and Business Operations (Details) [Line Items]
Public share (in Dollars per share)					$ 10

Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended		9 Months Ended
	Oct. 05, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Cash (in Dollars)		$ 46,617		$ 46,617		$ 196,510
Effective tax rate		103.11%	0.00%	112.31%	0.00%
Statutory tax rate		21.00%	21.00%	21.00%	21.00%
Federal depository insurance coverage (in Dollars)				$ 250,000
Common stock to redemption value (in Dollars)				$ 11,986,633
Subsequent Event [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Redeemed public stockholders	$13,082,703

Summary of Significant Accounting Policies (Details) - Schedule of Condensed Statement of Operations - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Schedule of Condensed Statement of Operations [Abstract]
Net income (loss)	$ (2,739)	$ 189,391	$ (224,171)	$ 5,014	$ (4,967)	$ (7,318)	$ (37,519)	$ (7,271)
Accretion of common stock to redemption value	(388,700)						(8,576,993)
Net income (loss) including accretion of common stock to redemption value	$ (391,439)			$ 5,014			$ (8,614,512)	$ (7,271)

Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net Income (Loss) Per Common Stock - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Redeemable share [Member]
Numerator:
Allocation of net income (loss) including accretion of common stock	$ (248,949)		$ (6,270,820)
Accretion of common stock to redemption value	388,700		8,576,993
Allocation of net income (loss)	$ 139,751		$ 2,306,173
Denominator:
Basic weighted average shares outstanding (in Shares)	2,904,816		4,448,538
Basic net income (loss) per share (in Dollars per share)	$ 0.05		$ 0.52
Non- redeemable shares [Member]
Numerator:
Allocation of net income (loss) including accretion of common stock	$ (142,490)	$ 5,014	$ (2,343,692)	$ (7,271)
Accretion of common stock to redemption value
Allocation of net income (loss)	$ (142,490)	$ 5,014	$ (2,343,692)	$ (7,271)
Denominator:
Basic weighted average shares outstanding (in Shares)	1,662,623	1,250,000	1,662,623	1,250,000
Basic net income (loss) per share (in Dollars per share)	$ (0.09)	$ 0	$ (1.41)	$ (0.01)

Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net Income (Loss) Per Common Stock (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Redeemable share [Member]
Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net Income (Loss) Per Common Stock (Parentheticals) [Line Items]
Diluted weighted average shares outstanding	2,904,816		4,448,538
Diluted net income (loss) per share	$ 0.05		$ 0.52
Non- redeemable shares [Member]
Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net Income (Loss) Per Common Stock (Parentheticals) [Line Items]
Diluted weighted average shares outstanding	1,662,623	1,250,000	1,662,623	1,250,000
Diluted net income (loss) per share	$ (0.09)	$ 0.00	$ (1.41)	$ (0.01)

Summary of Significant Accounting Policies (Details) - Schedule of Common Stock Subject to Possible Redemption - USD ($)

9 Months Ended

12 Months Ended

Oct. 04, 2022

Sep. 30, 2023

Dec. 31, 2022

Schedule of Common Stock Subject to Possible Redemption [Abstract]

Gross proceeds

$ 50,000,000

$ 2,109,200

$ 52,730,000

Less:

Proceeds allocated to public warrants

(3,532,910)

Proceeds allocated to public rights

(1,845,550)

Allocation of offering costs related to redeemable shares

(3,932,347)

Plus:

Accretion of carrying value to redemption value

8,576,993

3,409,640

Redeemed public stockholders

^[1]

(35,224,086)

Common stock subject to possible redemption

$ 20,181,740

$ 46,828,833

[1]	Includes $13,082,703 payment to redeemed public stockholders which was made on October 5, 2023.

Initial Public Offering (Details) - USD ($)			9 Months Ended	12 Months Ended
Initial Public Offering (Details) - USD ($)	Oct. 07, 2022	Oct. 04, 2022	Sep. 30, 2023	Dec. 31, 2022
Initial Public Offering (Details) [Line Items]
Shares issued		5,000,000
Share per unit (in Dollars per share)		$ 10
Gross proceeds (in Dollars)		$ 50,000,000	$ 2,109,200	$ 52,730,000
Option to purchase shares		750,000
Initial public offering description			Each Public Unit consists of one share of common stock (“Public Share”), one right (“Public Right”) and one redeemable warrant (“Public Warrant”). Each Public Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination.
IPO expiration			5 years
Public shares sold			5,273,000
Over-Allotment Option [Member]
Initial Public Offering (Details) [Line Items]
Gross proceeds (in Dollars)	$ 2,730,000
Option to purchase shares	273,000
Price per unit (in Dollars per share)	$ 10
Warrant [Member]
Initial Public Offering (Details) [Line Items]
Price per unit (in Dollars per share)			$ 11.5

Private Placement (Details)	9 Months Ended
Private Placement (Details)	Sep. 30, 2023 USD ($) $ / shares shares
Private Placement (Details) [Line Items]
Aggregate purchase price (in Dollars) \| $	$ 2,605,000
Sale of additional private units (in Shares) \| shares	8,873
Price per unit	$ 10.15
Private placement description	Each Private Unit consists of one share of common stock (“Private Share”), one right (“Private Right”) and one redeemable warrant (“Private Warrant”). Each Private Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination.
IPO [Member]
Private Placement (Details) [Line Items]
Purchase of private placement (in Shares) \| shares	260,500
Sponsor [Member]
Private Placement (Details) [Line Items]
Price per share	$ 10
Private Unit [Member]
Private Placement (Details) [Line Items]
Generating total proceeds (in Dollars) \| $	$ 88,725
Private Warrants [Member]
Private Placement (Details) [Line Items]
Price per unit	$ 11.5
Sponsor [Member] \| Private Unit [Member]
Private Placement (Details) [Line Items]
Price per unit	$ 10

Related Party Transactions (Details) - USD ($)					3 Months Ended	9 Months Ended	12 Months Ended
Related Party Transactions (Details) - USD ($)	Oct. 07, 2022	Oct. 04, 2022	Sep. 25, 2021	Sep. 05, 2021	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 26, 2023	Sep. 12, 2023	Jun. 26, 2023	Mar. 22, 2023
Related Party Transactions (Details) [Line Items]
Common stock shares issued (in Shares)			1,437,500
Aggregate consideration			$ 25,000
Price per share (in Dollars per share)					$ 10.15	$ 10.15
Issued and outstanding shares percentage						20.00%
Founder shares forfeited (in Shares)		119,250
Founder shares outstanding (in Shares)	1,318,250
Founder shares percentage						50.00%
Common stock equals or exceeds per share (in Dollars per share)					$ 0.0001	$ 0.0001	$ 0.0001
Aggregate amount				$ 200,000
Repaid outstanding balance	$ 200,000
Sponsor converted the outstanding balance to promissory note	$ 155,025
Sponsor loaned								$ 47,227	$ 150,000	$ 240,000	$ 200,000
Outstanding promissory note						$ 792,252	$ 155,025
Convertible loan amount					$ 1,500,000	$ 1,500,000
Convertible price per unit (in Dollars per share)					$ 10	$ 10
Sponsor pay amount						$ 10,000
Incurred amount					$ 30,000	90,000
Administrative fees						$ 118,387	$ 28,387
Founder Shares [Member]
Related Party Transactions (Details) [Line Items]
Price per share (in Dollars per share)			$ 0.017
Over-Allotment Option [Member]
Related Party Transactions (Details) [Line Items]
Shares subject to forfeiture (in Shares)					187,500	187,500
IPO [Member]
Related Party Transactions (Details) [Line Items]
Received amount from related party						$ 155,025
Business Combination [Member]
Related Party Transactions (Details) [Line Items]
Founder shares percentage						50.00%
Common stock equals or exceeds per share (in Dollars per share)					$ 12.5	$ 12.5

Commitments and Contingency (Details) - USD ($)		9 Months Ended	12 Months Ended
Commitments and Contingency (Details) - USD ($)	Oct. 04, 2022	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingency (Details) [Line Items]
Underwriting discount percentage		1.75%
Gross proceeds	$ 50,000,000	$ 2,109,200	$ 52,730,000
Deferred fee percentage		4.00%
Underwriting Agreement [Member]
Commitments and Contingency (Details) [Line Items]
Gross proceeds		$ 922,775

Stockholders' Equity (Details) - $ / shares		9 Months Ended	12 Months Ended
Stockholders' Equity (Details) - $ / shares	Oct. 04, 2022	Sep. 30, 2023	Dec. 31, 2021	Dec. 31, 2022
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized		16,000,000		16,000,000
Common stock par value (in Dollars per share)		$ 0.0001		$ 0.0001
Vote for each share		one
Common stock shares issued		1,662,623	1,437,500	1,662,623
Common stock shares outstanding		1,662,623	1,437,500	1,662,623
Initial stockholders percentage			20.00%
Founder shares were forfeited	119,250
Common stock subject to possible redemption, shares issued		1,913,012		5,273,000
Common stock subject to possible redemption, shares outstanding		1,913,012		5,273,000
Redeem outstanding warrants description		●in whole and not in part; ●at a price of $0.01 per warrant; ●upon a minimum of 30 days’ prior written notice of redemption, which the Company refers to as the 30-day redemption period; ●if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the to the warrant holders.
Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Common stock par value (in Dollars per share)		$ 11.5
Warrant expiration		5 years
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Founder shares			187,500
Business Combination [Member]
Stockholders' Equity (Details) [Line Items]
Common stock par value (in Dollars per share)		$ 12.5
Business combination description		Rights — Each holder of a right will receive one-tenth (1/10) of one share of common stock upon consummation of a Business Combination, even if the holder of such right redeemed all shares held by it in connection with a Business Combination. No fractional shares will be issued upon conversion of the rights. No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares upon consummation of a Business Combination, as the consideration related thereto has been included in the Unit purchase price paid for by investors in the Initial Public Offering. If the Company enters into a definitive agreement for a Business Combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the common stock will receive in the transaction on an as-converted into common stock basis and each holder of a right will be required to affirmatively convert its rights in order to receive one-tenth (1/10) of one share underlying each right (without paying additional consideration). The shares issuable upon conversion of the rights will be freely tradable (except to the extent held by affiliates of the Company).

Fair Value Measurements (Details) - Schedule of Company’s Assets that are Measured at Fair Value on a Recurring Basis - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Assets
Marketable securities held in Trust Account	$ 33,720,333	$ 53,958,681
Quoted Prices in Active Markets (Level 1)
Assets
Marketable securities held in Trust Account	33,720,333	53,958,681
Significant Other Observable Inputs (Level 2)
Assets
Marketable securities held in Trust Account
Significant Other Unobservable Inputs (Level 3)
Assets
Marketable securities held in Trust Account

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Oct. 04, 2023	Oct. 31, 2023	Oct. 26, 2023
Subsequent Events (Details) [Line Items]
Amount paid	$ 13,082,703
Business Combination transaction costs			$ 145,000
Deposit		$ 63,129

Qomolangma Acquisition (NASDAQ:QOMOU)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Qomolangma Acquisition Charts.

Qomolangma Acquisition (NASDAQ:QOMOU)
Historical Stock Chart
From Apr 2023 to Apr 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

QOMOU Qomolangma Acquisition Corporation

Qomolangma Acquisition Corporation News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

QOMOU Qomolangma Acquisition Corporation

Qomolangma Acquisition Corporation News

Your Recent History

Company

Business

Popular

Get The App